CB 1267

Drug Profile

CB 1267

Latest Information Update: 23 Aug 2002

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Cedars-Sinai Health System; LEO Pharma; Nonindustrial source
  • Developer Cedars-Sinai Health System; Nonindustrial source
  • Class Antineoplastics; Vitamin D analogues
  • Mechanism of Action Protein synthesis inhibitors; Vitamin D3 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 23 Aug 2000 Discontinued - Preclinical for Cancer in USA (unspecified route)
  • 10 Jan 2000 A preclinical study has been added to the pharmacodynamics section
  • 13 Jan 1997 Preclinical development for Cancer in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top